April 3, 2017 / 11:45 AM / 5 months ago

BRIEF-Versartis reports new data on Somavaratan in growth hormone deficiency

April 3 (Reuters) - Versartis Inc

* Versartis reports new data on long-acting Somavaratan in growth hormone deficiency at endo 2017

* Baseline characteristics of phase 3 velocity trial population balanced between study arms and comparable to phase 2

* Further results from vital trial in adult ghd-similar Somavaratan PK/PD data in U.S., Japanese children support using same dose in ongoing phase 3 trials Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below